Amarin Corp Plc (AMRN)

[Number sleven]

RMB, That is why the suit is important. It's also why Hikma is tying itself in knots to keep it out of the court. A deal like this shows both intent and action. It's also the way every generic company is exploiting their skinny label approval. Until a court set's precedent it will continue. GSK v Teva opened the door that Amarin is walking through. The advertising error that Hikma made has the potential to end generic abuse of the skinny label.
Sleven,